Non-Hodgkin's Lymphoma
Conditions
Brief summary
Non-Hodgin's lymphoma is curable in 76% of patients. In nonlymphoblastic lymphmas, cancer may return on average 3 months from beginning treatment and for lymphoblastic lymphomas, 6 months. To aggressively treat this cancer this study uses effective drugs in three parts: * Induction ends on day 19 * Consolidation ends on day 38 or 42 * Maintenance may include up to 6 cycles
Interventions
DRUGLSA4, Cyclophosphamide, Methotrexate, Daunomycin, L-asparaginase, BCNU
LSA4 intervention includes three phases: induction, consolidation and maintenance
Sponsors
Memorial Sloan Kettering Cancer Center
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
No minimum to 21 Years
Healthy volunteers
No
Inclusion criteria
* Non-Hodgkin's Lymphoma stages III, IV, IVA with 1. T cell lymphomas, any primary site irrespective of LDH level 2. large cell lymphomas, any primary site irrespective of LDH level 3. B cell lymphomas, any primary site with initial LDH of less than 500
Exclusion criteria
* B cell lymphomas, any primary site with initial LDH of less than 500 and initial CNS or bone involvement
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Complete Remission | 330 Days | The number of patients who achieved a complete remission as a result of treatment |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| All Patients LSA4, Cyclophosphamide, Methotrexate, Daunomycin, L-asparaginase, BCNU: LSA4 intervention includes three phases: induction, consolidation and maintenance | 17 |
| Total | 17 |
Baseline characteristics
| Characteristic | All Patients |
|---|---|
| Age, Customized Median Age | 12 years |
| Sex: Female, Male Female | 5 Participants |
| Sex: Female, Male Male | 12 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | — / — |
| other Total, other adverse events | 17 / 17 |
| serious Total, serious adverse events | 1 / 17 |
Outcome results
Primary
Complete Remission
The number of patients who achieved a complete remission as a result of treatment
Time frame: 330 Days
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| All Patients | Complete Remission | 10 participants |